Page 32 - Journal of Structural Heart Disease Volume 1, Issue 3

Original Scientific Article 138
Figure 1. Repositionable valved stent (Zegdi et al. réf 11). A, B and C. Representation of the principle of compression-relaxation of the valved stent. After deployment of the nitinol self-expandable device (A), the stent can be reversibly compressed (B) by exerting traction on the encircling suture through a proximal handle (C). D. Fluoroscopy, positioning of the valved stent within a tricuspid bioprosthetic valve. E. Macroscopic posterior view of the heart showing excellent positioning of the valved stented inside the failed tricuspid bioprosthesis.
Moreover secondary tricuspid valve disease with right ventricular failure is emerging as an Achilles heel for the management of a vast population of pa- tients with severe left sided heart failure, requiring assist devices.
Over the last decade, transcatheter aortic and pulmonary valve implantation has revolutionized the therapeutic options for patients at high risk for conventional surgery [5-8]. There has been growing interest in the field of interventional cardiology to percutaneously treat dysfunctional tricuspid valves. Although the data is less robust compared with tran- scatheter pulmonary or aortic valve replacement, several experimental and clinically useful interven-
tions to treat tricuspid valve dysfunction in various anatomical settings such as native tricuspid valves, annuloplasty rings or bioprosthesis have been de- scribed. In this review, we lay emphasis on different strategies and devices developed so far, which may serve as a useful platform for transcatheter therapy for tricuspid valve failure.
Percutaneous Treatment of Degenerated Tricuspid Bioprosthetic Valves: Valve-in-Valve Technique
Bioprosthetic cardiac valves are usually preferred in young patients due to reduced thromboembol-
Journal of Structural Heart Disease, August 2015
Volume 1, Issue 3: 137-151